Lantern Pharma is trading 12.47% up at $0.72 on October 28, 2026, amid biotech-sector strength; this backdrop is the likeliest explanation, but does not establish the precise cause.
- XBI is up 2.18%.
- Positive clinical-trial and regulatory news elsewhere in the industry supports the sector backdrop.
- Lantern Pharma’s latest official press-release listings show announcements dated October 8 and October 7, with no fresh company-specific catalyst explaining the move.